Ishita Drugs Board Approves Unaudited Q1 FY27 Results

Ishita Drugs & Industries Ltd announced the outcome of its Board meeting held on August 8, 2026. The Board approved the Unaudited Financial Results for the quarter ended June 30, 2026. Key decisions included the re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director, subject to shareholder approval. The Board also approved amendments to the notice for the 33rd Annual General Meeting and accepted a revised remuneration proposal for the CFO, Mr. Sumit Agrawal. Significant progress was reported on the manufacturing facility upgradation project, with approximately ₹435 lakh spent and capital contracts of ₹565 lakh issued for utilities and equipment. The company is also in discussions to raise funds for this project.